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Abstract
Ligands that can selectively bind to proteins with single amino acid point mutations offer the 
potential to detect or treat an abnormal protein in the presence of the wildtype. However, it is 
difficult to develop a selective ligand if the point mutation is not associated with an addressable 
location, such as a binding pocket. Here we report an all-chemical, synthetic epitope-targeting 
strategy which we used to discover a 5-mer peptide with selectivity for the E17K transforming 
point mutation in the Pleckstrin Homology Domain of the Akt1 oncoprotein. A fragment of Akt1 
containing the E17K mutation and a I19[Propargylglycine] substitution was synthesized to form 
an addressable synthetic epitope. Azide-presenting peptides that covalently clicked onto this 
alkyne-presenting epitope were selected from a library using in situ screening. One peptide 
exhibits a 10:1 in vitro selectivity for the oncoprotein relative to wildtype, with a similar 
selectivity in cells. This 5-mer peptide was expanded into a larger ligand that selectively blocks 
the E17K Akt1 interaction with its PIP3 substrate.
Ligands that selectively bind to proteins with single amino acid point mutations are 
becoming increasingly important for both diagnostics and therapeutics. In a diagnostic 
setting, such binders can be used to assay for the mutant protein within diseased tissues, and 
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thus potentially provide clinical guidance for treatment decisions1. A more ambitious 
application is the development of drugs that can selectively inhibit mutant proteins and thus 
avoid the toxic side-effects that stem from the inhibition of the wild-type (WT) variants2 that 
reside in non-diseased tissues. A relevant example is compound CO-1686, which is an a 
epidermal growth factor receptor (EGFR) inhibitor specific for the T790M point mutation 
associated with certain non-small cell lung carcinomas. That small molecule drug, which is 
currently in trials, is designed to minimize the toxicities (such as skin rash) that can appear 
when WT EGFR is targeted, since WT EGFR is expressed throughout the healthy tissues in 
the body3.
A challenge of developing a drug targeting a single point mutation is that the mutation may 
not be directly associated with a binding pocket. The presence of a binding pocket is 
traditionally required for small molecule inhibitor development. This requirement does not 
hold for antibodies and, in fact, several examples of monoclonal antibodies directed against 
epitopes containing single amino acid mutations do exist4,5,6. However, antibodies do not 
readily enter the living cells that can harbor the mutated proteins7,8, and so mutation-
selective antibodies are typically only used as diagnostic reagents for staining fixed cells or 
tissues. Thus, there is a need for an approach to identify molecules that can be targeted 
against epitopes containing single amino acid point mutations, and which can potentially be 
developed into cell-penetrant inhibitors9. Here we report on an all-chemical epitope 
targeting strategy that focuses ligand development specifically to the E17K oncogenic point 
mutation of Akt1 (Akt1E17K). We use this technique to develop a short-chain peptide to bind 
to Akt1E17K, and we take the first steps towards developing that binder into a cell-penetrant, 
mutant-selective inhibitor.
Akt1 kinase plays a critical role in the PI3K signaling pathway10 – the activation of which is 
closely linked to tumor development and cancer cell survival11. The recently discovered 
E17K mutation in the Pleckstrin Homology Domain (PH Domain) of Akt1 results in an 
increased affinity for the phosphatidylinositol (3,4,5)-trisphosphate (PIP3) substrate at the 
cell membrane12. Consequently, this deregulated recruitment of Akt1 to the cell membrane 
causes constitutive activation of the PI3K pathway, which has been shown to induce 
leukemia in mice12. The oncogenic properties of Akt1E17K make it a target for both 
detection and inhibition.
We recently reported on a strategy for focusing peptide ligand development near 
phosphorylation sites13. For that approach, a protein fragment representing the 
phosphorylated epitope of interest was synthesized, and a metal organic Zn-chelator was 
utilized to bind to the phosphate group and present an azide near that site. The azide-
containing Zn-chelator was used as an anchor to focus the in situ click screening of a one-
bead, one-compound (OBOC) library of 5-mer alkyne-presenting peptides to the phospho-
site of the protein fragment. This basic approach was restricted to the targeting of naturally 
addressable residues, and required a separate anchor ligand. Using this technique, peptide 
ligands with high selectivity for the Akt2 isoform, and with affinities as low as 19 nM were 
developed. We have called the class of peptide ligands identified through in situ click 
screening Protein Catalyzed Capture agents, or PCC agents.13–18 A technical goal for the 
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present work was to develop a method for synthetically introducing this addressable residue, 
potentially extending the generality of the technique.
Our epitope-targeting, small molecule approach, although 100% synthetic, is inspired by the 
biological technique for developing an epitope-targeted monoclonal antibody (mAb). Such 
mAbs are often developed by injecting a small fragment of the protein of interest containing 
the mutation (the epitope), into an animal, and screening for an immune response that has 
the desired selectivity5,6,4. We report here on a targeting strategy that directly substitutes an 
alkyne click handle into a chemically-synthesized peptide epitope which makes an easily 
addressable residue for selectively targeting a region of interest in a protein. This technique 
potentially eliminates the need for a binding pocket or a naturally addressable residue such 
as a phosphorylation site. For this work, the peptide represents the epitope of Akt1 
containing the E17K point mutation. The epitope target is subjected to an in situ click screen 
against an OBOC peptide library of 5-mers (comprehensive in 18 amino acids), each 
terminated in an azide-presenting amino acid. For such a screen, the protein fragment 
provides a highly-selective scaffold that replaces the Cu(I) catalyst typically used in 
promoting the cyclo-addition between the alkyne and azide groups to form a triazole linkage 
(the Huisgen click reaction)14. Hits are defined as those compounds that are covalently 
coupled to the synthetic epitope through a triazole linkage. The juxtaposition of the 
chemically-substituted alkyne click handle to the E17K point mutation should mean that any 
hit peptide that has been covalently linked to the target sequence should bind in close 
proximity to the mutation.
This technique allowed us to focus our PCC agent development to a location on the PH 
Domain that was adjacent to the E17K oncogenic mutation. We identified a 5-mer peptide 
that exhibited a 10:1 selectivity for Akt1E17K relative to WT. We exploited the chemical 
flexibility and modularity of the PCC agent to append a dye and a cell penetrating peptide. 
The resultant ligand could preferentially localize in live cells expressing Akt1E17K, again 
with high selectivity relative to WT. Finally, we developed the PCC agent into a biligand 
and then a triligand through the use of iterative in situ click chemistry14. We showed that 
these larger PCC agents could serve as highly selective inhibitors of Akt1E17K by blocking 
binding of the Pleckstrin Homology Domain of Akt1 to the PIP3 substrate.
Results
In situ click epitope-targeted screening strategy for E17K PH Domain-specific ligand
Using FMOC solid-phase peptide synthesis (SPPS) techniques19 a polypeptide representing 
residues 1–32 of the E17K PH Domain of Akt1 was synthesized. From the crystal structure 
(2UZR) (Fig. 1), these residues form a β-sheet around the E17K mutation (blue). The 
epitope fragment was appended with an N-terminal PEG5-biotin to serve as a detection 
handle when screening. This manual synthesis of the epitope allowed for an I19Pra 
substitution (Pra = Propargylglycine) to provide an alkyne click handle on the most proximal 
side-chain residue to the E17K mutation. Following chromatographic purification, and 
characterization via circular dichroism (Supplemental Fig. S1), the modified epitope was 
ready for screening.
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A single generation in situ click screen can yield ligands with a high selectivity for the 
target. The in situ click reaction itself is low yielding14, but the biotin handle on the 
synthetic epitope permits the delineation of those beads that contain the covalently coupled 
epitope (the hits). This is done using a colorimetric streptavidin-linked alkaline phosphatase 
assay. The basic screening strategy is shown in Supplemental Figure S2. Out of the 
theoretical 1.5 million library members that were screened against the alkyne-containing 33-
mer E17K PH Domain fragment, only 21 beads (0.0015%) showed the presence of the 
covalently coupled epitope. These beads were sequenced using Edman degradation 
(Supplemental Tables S1 and S2). The hits were segregated based on their hydrophobicity 
and sequence homology using principal component analysis (Supplemental Fig. S3). Five 
ligands that represented the diversity of hits (circled in Supplemental Fig. S3) were scaled-
up and tested for binding to both E17K and WT full-length PH Domain proteins. 
Immunoprecipitation assays (Supplemental Fig. S4) were used to probe for differential 
binding to the proteins in buffer. One ligand candidate showed a distinctively stronger 
binding to the E17K PH Domain relative to the WT. This peptide, sequence “yleaf”, (Fig. 
2a) was carried forward for additional investigations. Here the lower case sequence letters 
indicate that the amino acids that comprise the peptide are (non-natural) D-stereoisomers.
Verification of epitope targeting strategy
The label-modified yleaf peptide (Fig. 2a) was subjected to a variety of binding assays 
against the synthesized WT and E17K 33-mer PH Domain fragments prepared without the 
biotin label and alkyne click handle. First, the yleaf peptide was used in 
immunoprecipitation pull-down assays to pull from solution either the WT or E17K mutant 
6-His-tagged 33-mer peptide fragments, as opposed to the full-length proteins that were used 
to initially validate the candidates. Typical immunoprecipitation assays involve western 
blotting to estimate the amount of protein binding, but small peptide fragments are not easily 
quantified on a blot. Because of this, the amount of peptide epitope precipitated in these 
assays was quantified via injection on an analytical HPLC. These assays further confirmed 
preferential yleaf ligand binding to the E17K 33-mer epitope relative to the WT epitope 
(Supplemental Fig. S5). As an assay control, another candidate ligand that, in initial testing, 
did not exhibit preferential E17K binding to the full protein, was tested, and yielded 
consistent results.
The selectivity of the yleaf peptide for the E17K 33-mer epitope was also tested in an 
ELISA assay format. For these assays, the WT or E17K 33-mer peptide fragments were 
captured using the PEG-biotin-modified yleaf ligand immobilized on a Neutravidin-coated 
plate. The yleaf ligand exhibited significant selectivity for the E17K fragment over the WT 
across a 100 nM – 1 μM concentration range (Fig. 2b) This selectivity was quantified by 
measuring the KD values for the binding of the yleaf peptide to both epitope fragments (Fig 
2d), as well as full length Akt1 and Akt1E17K (Fig 2c, Supplemental Fig. S6) via 
fluorescence polarization (FP). The yleaf peptide exhibited KD values of 328 ± 96 nM and 
54 ± 7.0 nM for the mutant epitope and for full length Akt1E17K, respectively. These 
compare to KD values of 2.8 ± 0.84 μM and > 1 μM shown for the WT epitopes and Akt1, 
respectively. These results confirm the highly selective nature of the epitope targeting 
Deyle et al. Page 4
Nat Chem. Author manuscript; available in PMC 2015 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
strategy, and demonstrate that high selectivity achieved through that strategy is retained for 
the full length protein.
Ligand-directed labeling experiment to confirm epitope targeting
The binding of the yleaf ligand onto Akt1E17K was further explored using the directed 
labeling technique reported by Tsukiji et al20. The approach yields information relative to 
the binding location of the ligand on the protein target. For this method, a payload is 
attached to the N-terminus of the targeting yleaf ligand through an electrophilic phenyl 
sulfonate linker. Upon ligand binding to the protein target, the payload is transferred onto 
the protein through an SN2 reaction with proximal nucleophilic amino acid side chains (Fig. 
3a). The protein can then be trypsin digested and the identity of the fragments containing the 
payload can be mapped on the protein surface using mass spectrometry (MS). Thus, the site 
of ligand binding can be estimated. The assay also serves as an independent validation of the 
binding assays discussed above.
For the assay, yleaf was modified at the N-terminus to contain a tosylate linker attached to a 
Cy5 dye molecule to enable easy identification of the labeled and digested protein fragments 
(Fig. 2a). A Glutathione S-Transferase (GST)-Akt1E17K protein (SignalChem) was 
incubated with the Cy5-appended yleaf. The labeling of protein target was initially 
confirmed by visualization on a fluorescent gel reader (Fig. 3b), as well as a Western 
blotting visualization of an experiment in which a biotin-label was substituted for the 
fluorescent tag (Supplemental Fig. S7). The labeled protein and an unlabeled control were 
then trypsin digested from the gel and were analyzed by matrix-assisted laser desorption/
ionization time-of-flight (MALDI-TOF) MS (Supplemental Figs. S8 and S9). Five peaks 
appeared in the MS of the labeled protein that were not present in the unlabeled protein 
digests. Those peaks all corresponded to an expected trypsin fragment plus the weight of the 
linker and dye. These peaks were then analyzed by MALDI-TOF/TOF MS to extract 
sequence information for the labeled regions of the protein. All but one of the dye labeled 
peptides were difficult to fragment, as is characteristic of cationic peptide labels21. The 
labeled digest YFLLK could be fragmented (Supplemental Fig. S10) and indicated the 
presence of the dye on the Y amino acid. The labeling can be seen clearly when compared to 
the unlabeled YFLLK upon fragmentation (Supplemental Fig. S11). This is consistent with 
the original literature on the labeling technique20 which showed that Y, E and H amino acids 
are the nucleophiles that can be labeled. The other labeled Akt1E17K fragments that were 
identified contain at least one of these amino acids. One fragment contains two such amino 
acids and, in fact, there were MALDI-TOF peaks corresponding to the masses of both the 
singly and doubly labeled fragment. Supplemental Figure S12 shows the location of the 
labeled fragments in the PH Domain sequence, as well as the amino acids that should 
contain the label.
The labeling sites were then mapped on a composite crystal structure of GST (PDB: 1UA5) 
and Akt1E17K (Akt PDB: 3096, E17K PDB: 2UZR) (Supplemental Fig. S12, Fig. 3c). All 
labeled sites surround the epitope originally used in screening, which is the anticipated 
binding site of the yleaf ligand. A thorough search of the entire MALDI spectra was 
conducted to identify any other labeled fragments anywhere on the large protein, but none 
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were found. Thus, this experiment demonstrates that only sites around the expected N-
terminal binding site of the yleaf ligand are labeled, confirming the very specific binding of 
the peptide ligand at the site directed by the epitope-targeted in situ click screening process.
Cell Imaging
Cell based assays can provide a demanding environment for demonstrating the selectivity of 
the yleaf PCC agent to Akt1E17K. To demonstrate target binding in a complex cellular 
milieu, HEK-293T cells were transfected to express GFP-tagged E17K or GFP-tagged WT 
PH Domain proteins. The yleaf ligand was then labeled with both a Tat cell-penetrating 
peptide22 and a Cy5 dye (Fig. 2a). The combination of the GFP label on the protein and the 
Cy5 label on the dye permitted the use of multi-color fluorescence microscopy for 
interrogating any spatial registry between the two fluorescent labels, as well as tracking the 
efficiency of the protein expression in the cells. Live HEK-293T cells expressing these GFP-
tagged proteins were exposed to varying concentrations of the modified yleaf anchor ligand 
for one hour. The cells were then incubated in fresh media for one hour before being 
thoroughly washed in PBS to remove weakly and nonspecifically bound PCC and fixed for 
fluorescence microscopy measurements (see Supplemental Fig. S13 for a comparison of the 
anchor ligand retention before and after the buffer incubation step).
Confocal microscopy images of the two differentially expressing Akt1 PH Domain cells 
showed a consistent level of expression between the GFP-WT PH Domain and GFP-E17K 
PH Domain. However, the level of the PCC agent retained by the cells was substantially 
different (Fig. 4, for control images, see Supplemental Figs. S14–S15). Nearly all of the 
cells expressing the mutant protein show PCC agent retention and demonstrate some level of 
co-localization of PCC agent and GFP-PH Domain protein. The GFP-PH Domain WT cells, 
however, show very low levels of PCC agent retention. Pearson’s correlation coefficient was 
used to quantify the co-localization of the two different dyes23 by calculating over four 
representative images for each of the WT or E17K mutant cells and averaging the results. In 
a perfect correlation event the Pearson coefficient would be equal to 1, while no correlation 
equals 0, and a perfect negative correlation would produce a value of −1. The cells 
expressing GFP-PH Domain WT protein have an average correlation coefficient of r = 0.14 
± 0.06, implying little correlation, whereas the cells expressing the GFP-PH Domain E17K 
mutant protein have an average coefficient of r = 0.47 ± 0.13. These Pearson coefficients 
show a statistically significant difference between the two sets of images (p = 0.0045). The 
Cy5 fluorescence intensity on a per cell basis has also been calculated for the cells 
expressing the WT and E17K proteins (Supplemental Fig. S13), and this difference is again 
statistically significant (p = 0.00018). These assays demonstrate the selectivity of the E17K 
PCC agent for its target within live cells.
Biligand and triligand development
There is an interest in compounds that can selectively inhibit a disease-associated mutated 
protein target while sparing the WT variant2. PH Domain inhibiting compounds24,25 with 
selectivity for Akt1E17K have not been reported. The proximity of the E17K mutation to the 
PIP3 binding site prompted us to consider further developing this PCC agent into a 
compound capable of selectively blocking the E17K PH Domain interaction with its PIP3 
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substrate. The yleaf peptide itself did not exhibit evidence of inhibition (Fig. 5d). We 
reasoned that a similarly targeted, but bulkier PCC agent might serve as a steric blocker of 
the PH Domain-PIP3 interaction. To this end, we executed two cycles of iterative in situ 
click chemistry screens (Fig. 5a)26 to develop the yleaf ligand into a biligand, and then a 
triligand. To identify the biligand (the first cycle), the yleaf ligand was modified to present 
an alkyne at the C-terminus and a PEG5-biotin group at the N-terminus. This modified yleaf 
anchor ligand was then co-incubated with an azide-presenting OBOC library and the 
(unmodified) E17K PH Domain protein. Successful hits are those in which the E17K PH 
Domain promotes the click coupling of the anchor ligand onto a library peptide, and those 
hits are detected by screening for the formation of this clicked product. Those hits are 
candidate 2° ligands. For testing, the 2° ligand candidates are appended to the yleaf anchor 
ligand via a Cu catalyzed 1,4 triazole linkage to form a biligand. The biligand candidates are 
then tested for affinity and specificity in a manner that is similar to what was done to 
identify the original yleaf ligand. Once a biligand is identified, it is modified to form a new 
anchor ligand, which is then similarly screened to identify a triligand. Screening details, 
including candidate hit sequences that were tested at both the biligand and triligand stage, 
are provided in the supplementary materials (Fig. S16 – S21 and Tables S4, S5). Several 
examples of PCC agent biligands or triligands and related screening techniques have been 
reported16. The triligand structure is shown in Figure 5b.
The final biligand and triligand sequences were chosen to retain a high selectivity of binding 
to Akt1E17K relative to WT. This was challenging, considering that Akt1E17K and the WT 
are sequence identical away from the E17K mutation. A comparison of the yleaf ligand, the 
biligand, and the triligand in binding assays against both full length proteins is provided in 
Supplementary Figure S21. In those assays, as well as in fluorescence polarization 
measurements of KD values, the triligand exhibited a selectivity for Akt1E17K (KD=115 ±8.7 
nM) relative to WT (KD=1.2 ±0.180 μM) that was similar to the yleaf anchor. Furthermore, 
there is a slight preference for Akt1E17K relative to the Akt2E17K (Supplementary Fig. S22). 
The homology of the PH Domain between these isoforms is 79%. In addition to the 
specificity for homologous proteins, the anchor and triligand were tested for their 
performance in 1% and 2% human serum (Supplemental Fig. S23). This assay shows very 
little reduction in binding efficiency in increasing amounts of serum, indicating that there 
are not significant off-target interactions with any proteins found in human serum.
Inhibition assays
The yleaf ligand, the biligand, and the triligand were all tested for their ability to block the 
E17K PH Domain binding with PIP3. For this test, PIP3-coated resin (Echelon Biosciences) 
was used to mimic the PH Domain interaction with the cell membrane, and could be used to 
bind the protein as in an immunoprecipitation assay25. The presence of an effective blocking 
compound would reduce the ability of the resin to capture the protein, and would thus 
appear as a diminished signal in the corresponding western blot assay. A control lane 
containing no PCC agent was used to show baseline binding of the protein to the PIP3 resin. 
Although the yleaf ligand produced no change in E17K binding ability, both the biligand 
and triligand did block the PH Domain-PIP3 interaction, with the triligand being the most 
effective (Fig. 5d). In an expanded study, we compared the amount of E17K and WT PH 
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domain binding relative to the amount of added triligand (Fig. 5e). This assay shows 
significant selective inhibition of the E17K mutant relative to the WT.
Discussion
The all-synthetic epitope targeting strategy described here provided an approach for 
developing a PCC agent peptide ligand that could be used to specifically detect an 
oncoprotein possessing a single transforming point mutation. The approach is conceptually 
simple and may be broadly applicable: a fragment of the target protein that contains the 
point mutation is chemically synthesized so that it presents a click handle near that mutation. 
That fragment (the epitope) is then subjected to an in situ click screen against a large library 
of peptides that present the complementary click chemistry handle. Viable hit candidates are 
those library elements that are covalently coupled to the fragment via a triazole linkage 
catalyzed by the strong and specific binding of the candidate ligand to the epitope. In this 
work, a polypeptide fragment that represented residues 1–32 of the PH Domain of Akt1E17K 
was prepared with an I19Pra substitution that displayed an alkyne functionality near the 
E17K mutation. A single generation in situ click screen yielded a 0.0015% hit rate and a 
peptide sequence that exhibited an approximately 10:1 selectivity for the E17K PH Domain 
relative to WT, with binding constant (KD) of 54 ± 7.0 nM.
PCC agents are peptides, which allows for the straightforward incorporation of strategic 
chemical modifications so as to permit several experimental illustrations of the in vitro 
binding specificity of the peptide ligand to the E17K PH Domain of Akt1 as well as full-
length Akt1E17K. In particular, ligand-directed labeling was used to confirm that the 
approximate location of the ligand binding on the target protein was consistent with the 
epitope-targeting strategy. The yleaf ligand, when modified with a cell-penetrating peptide 
and a dye label, could also be used to deliver the E17K PH domain into live cells. Upon 
fixing and washing the cells, those cells containing the E17K PH domain preferentially 
retained the ligand relative to WT, and that retained ligand exhibited statistically significant 
spatial correlation with the GFP-labeled E17K PH domain.
The epitope-targeting approach was demonstrated through the very demanding application 
of identifying a ligand specific for a single amino acid point mutation. With the 
synthetically-included alkyne amino acid residue to focus the library screening, there are no 
apparent protein structural requirements such as the need for binding pockets or other 
naturally addressable residues. Extending this approach towards the development of ligands 
specific to traditionally undruggable proteins, to post-translational modifications (e.g. 
phosphorylated or glycosylated epitopes), or to macrocyclic library architectures known to 
increase cell permeability27 should be possible, and we are currently pursuing such routes. A 
working concept here is that the initial PCC agent ligand (the yleaf peptide in this current 
example) provides for the ability to bring different chemical interactions to a specific region 
of a specific protein. In this paper, we used the yleaf ligand to direct the covalent attachment 
of a payload to proximal amino acid side chains, or to bring a dye label to the protein target, 
or to bring a larger peptide framework that could disrupt the PH Domain - PIP3 interaction. 
The implication is that this epitope targeting strategy may permit the exploration of non-
Deyle et al. Page 8
Nat Chem. Author manuscript; available in PMC 2015 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
traditional drugging approaches that can open up interesting targets, such as AktE17K, for 
selective inhibition.
Methods
Peptide Synthesis and Characterization
All peptides described were synthesized using standard FMOC SPPS peptide chemistry, 
described in more detail in the supplemental information. Structures and characterizations of 
all peptides can be found in Supplemental Figures S24 – S34.
Design of Epitope-Targeting Anchor/Target Peptide
The 33-mer epitope fragment sequence used in these studies corresponds to the peptide 
sequence: MSDVAIVKEGWLKKRGKY[Pra]KTWRPRYFLLKNDG. This 33-mer 
fragment was capped with an N-terminal biotin label for detection in the screen.
In Situ Click Screen for Initial Anchor Peptide (Supplemental Fig. S2)
Anchor peptide screens were performed using a library28 containing an N-terminal azide 
click handle with varying carbon chain lengths – 2 carbon, 4 carbon and 8 carbon – for in 
vivo click with the Pra on the target 33-mer. The resin was first “precleared” by incubating it 
with the streptavidin-alkaline phosphatase and BCIP developer. It was then incubated with 
the epitope target for either 5 hours or overnight for the click reaction to occur, washed 
extensively, and developed using streptavidin-alkaline phosphatase and BCIP. Beads that 
turned purple were considered hits, picked, and sequenced via Edman degradation. More 
details on the screening process are available in the supplemental information.
Ligand-Directed Tosylate Labeling Experiments
For these assays, the yleaf anchor was appended with an N-terminal FMOC-piperidine-4-
carboxylic acid as a linker on 300mg of rink amide resin in NMP using standard FMOC 
amino acid coupling techniques. The resin was equilibrated in anhydrous DCM and 250μL 
of 3-(chlorosulfonyl)benzylchloride was added with 450μL of DIEA for 30 minutes at room 
temperature. Then 250μL of 2-(2-(2-aminoethoxy)ethoxy)ethanol, 450μL of DIEA and 
19mg DMAP in anhydrous DMC were added and incubated overnight, then 2eq Cy5 
carboxylic acid (Lumiprobe) was coupled at 37°C overnight using standard FMOC coupling 
techniques.
In order to label the protein, 50μL of full-length GST-E17K Akt1 (SignalChem) was treated 
with 10× molar excess of the anchor ligand with the tosylate dye label and incubated for two 
days at room temperature. The mixture was lyophilized after two days and then denatured by 
boiling in SDS-PAGE loading buffer. The labeled protein was run alongside an unlabeled 
control on an Any-KD gel from Biorad, then imaged on an Odyssey fluorescent gel reader at 
700nm emission (Fig. 3b). After confirming that labeling had occurred, the gel was stained 
with BioSafe Coomassie blue stain (BioRad) and the blue protein bands were cut out. The 
gel pieces were trypsin digested using the Pierce In-gel Digest Kit. The tryptic fragments 
from both the unlabeled and labeled protein digests were lyophilized to concentrate them, 
taken up in 2μL of 50% H2O/50% Acetonitrile and were analyzed by MALDI TOF MS 
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(Supplemental Figs. S8 and S9), then MALDI TOF/TOF MS to determine the exact labeling 
sites (Supplemental Figs. S10 and S11).
Images of anchor ligand in HEK-293T cells expressing PH Domains
The yleaf anchor ligand was synthesized with an N-terminal PEG5, TAT (YGRKKRRQRR), 
and Cy5 dye (Fig. 2a). HEK-293T cells were grown in DMEM media supplemented with 
10% FBS (both Invitrogen), 100× non-essential amino acid solution (Sigma), and PenStrep 
antibiotic (Invitrogen). Once the cells reached ~80% confluency, they were treated with 
trypsin to remove from the plate and split into small wells with a D-poly-lysine (BD) 
coverslip at approximately a 50% confluency in 1mL total volume. The cells were allowed 
to attach to the coverslips for approximately 24 hours, then were transfected to express 
either wildtype GFP-PH domain or E17K mutant GFP-PH domain proteins using 
XtremeGene HD transfection agent at a ratio of 3:1 transfection agent to DNA. Several 
wells were left untreated as no protein blanks (Figure S14). The cells were given 24 hours to 
express protein. They were then serum starved for one hour in DMEM media prepared as 
above, but without the FBS. After one hour, the Cy5-labeled anchor was added to the wells 
to a final concentration of 50nM. As the HEK-293T cells are expressing endogenous Akt1 
protein, this level was adjusted to give the lowest background signal possible. After a one 
hour incubation with the peptide, the cells were washed once in serum starved media, then 
incubated one hour in serum starved media to wash out any excess peptide (see Figure S13 
for a comparison of peptide with and without the one hour wash step). During this time, the 
cells were also treated with 10μg of Hoescht 33342 dye to stain the nuclei. The cells were 
then washed twice with cold PBS buffer, fixed with 10% Neutral Buffered Formalin 
Solution (Sigma) and glued onto microscope slides. Images were taken on a Zeiss LSM 510 
Meta NLO with Coherent Chameleon confocal microscope. The laser intensity and gain 
were fixed for all pairs of images between wildtype and mutant samples to ensure that the 
differences seen were not artificially created.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Epitope design strategy for in situ click screen
The full Akt1 PH Domain protein (grey) contains an E17K mutation (blue). To focus a 
chemical library screen on the region surrounding this mutation, only a portion of the PH 
Domain (pink) containing the E17K mutation was synthesized as a separate peptide epitope. 
Chemical synthesis of the epitope allowed for the substitution of the isoleucine at residue 19 
(yellow), the most proximal side-chain to the E17K mutation, with an alkyne-containing 
propargylglycine amino acid. This substitution focused the azide library screening directly 
to the site of the mutation. This in situ click screen format allows for the determination of 
peptides that bind in close proximity to the E17K mutation. Triazoles formed between an 
azide-containing library peptide and the alkyne-substituted epitope must be catalyzed by a 
molecular recognition event, indicating that the library peptide binds strongly near the 
mutation.
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Figure 2. Anchor ligand structure and characterization
(a.) The peptide anchor ligand, yleaf, which was discovered using the epitope-targeting 
technique. The different sets of R groups indicate the modifications that were made to 
perform the various experiments described. (b.) Point ELISA for specificity obtained by 
immobilizing biotinylated yleaf anchor ligand onto a Neutravidin plate, then incubating with 
a 6 His-tagged epitope. This assay demonstrates the preference of the biotinylated yleaf 
anchor ligand for the E17K mutant epitope while immobilized on a surface. (c.) Binding 
curves of yleaf anchor ligand to the full-length WT or E17K mutant Akt1 proteins obtained 
in solution by fluorescence polarization. A saturation point for the WT ligand was not 
reached due to the prohibitively high protein concentration required. (d.) Full binding curves 
of yleaf anchor ligand to the WT or E17K mutant epitopes. These fluorescence polarization 
curves demonstrate the significant preference of the yleaf ligand for the E17K mutation in 
both the full protein assay (c) and the epitope peptide assay (d). All assays were performed 
in triplicate and averaged. Error bars indicate standard deviation.
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Figure 3. Ligand-Directed Labeling Experiments
(a.) Schematic of the ligand-directed labeling reaction. The yleaf anchor ligand (red) binds 
to the PH Domain (grey), and a nucleophilic amino acid (Nu) on the protein surface attacks 
the tosyl group, transferring the dye (pink star) onto the protein near the anchor binding site. 
The protein was then digested and analyzed via MALDI-TOF MS to discover fragments that 
have increased in mass by the weight of the dye. This experiment was designed to locate 
areas of the protein that are in close proximity to the bound yleaf anchor. (b.) Fluorescent 
gel image of GST-Akt1-PH Domain prior to trypsin digestion. Lane 1 is ladder, lane 2 is 
unlabeled protein, and lane 3 shows fluorescently-labeled protein (and excess fluorescent 
ligand at the bottom), confirming that the reaction has taken place. (c.) This Pymol-
assembled fusion protein highlights the PH Domain (blue) and the 33-mer epitope fragment 
used for screening (pink). Sites containing a label on the GST-Akt1-PH Domain, as 
identified by MS analysis, are indicated in cyan. These results indicate that the yleaf anchor 
is binding only in the area of the epitope, and does not have off-target binding interactions 
with any other part of this large protein.
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Figure 4. Images of the Cy5-yleaf-PEG5-TAT peptide ligand in cells
(a.) The PH Domain was fused to green fluorescent protein (GFP) in order to visualize 
expression. The Cy5-yleaf-PEG5-TAT was added to live cells expressing the protein, 
washed extensively, and imaged. The panel shows the spatial map of GFP expression in 
green. The second panel shows the spatial map of the dye-labeled yleaf ligand, and the third 
panel shows DAPI-stained nuclei. The r values indicate the Pearson correlation coefficient 
between the GFP protein and the Cy5 anchor. As demonstrated by the difference in both the 
Cy5 signal and the Pearson correlation coefficients, the anchor ligand is retained in E17K 
mutant-expressing cells to a significant degree more than in the wildtype cells, indicating 
ligand binding and selectivity even in a complex cellular environment. (b.) Zoomed in image 
of cells expressing E17K mutant protein with anchor ligand showing significant Cy5 signal 
in the areas of the cells containing GFP-tagged protein. (c.) Schematic of the experimental 
design for the imaging experiments. The HEK-293T cells were transfected to express GST-
tagged WT or E17K mutant protein, then incubated with the CPP – anchor – Cy5 peptide. 
These cells were then incubated for one hour in media, then fixed and imaged.
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Figure 5. The PCC agent triligand development strategy, structure, and inhibition data
(a.) The yleaf anchor ligand appended with a C-terminal alkyne was screened against an 
azide-terminated library in the presence of the full-length PH Domain to identify a biligand. 
The biligand was then appended with an N-terminal azide and screened against an alkyne 
library to identify a triligand. (b.) The final triligand structure, which is color-coded to 
highlight each segment. (c.) Fluorescence polarization assays demonstrating triligand 
affinity for the WT (blue) and E17K (red) full-length proteins, indicating that the E17K 
mutant selectivity is retained by the triligand. All conditions were performed in triplicate 
and averaged. Error bars indicate standard deviation. (d.) Inhibition assays were performed 
with PIP3-coated resin that was incubated with constant concentrations of E17K mutant 
protein and each ligand. The blank measures the binding of the E17K PH Domain to PIP3 
with no ligand present. The decreased binding of the protein in the presence of the biligand 
and triligand indicates inhibition. (e.) Expanded inhibition assay with varying concentrations 
of triligand (indicated here as the molar ratio with respect to the protein) incubated with WT 
or E17K proteins. The only slight drop-off in WT binding indicates little inhibition of this 
protein, while significant inhibition is shown against the E17K variant.
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